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When it was discovered that a subclass of T  lymphocytes could specifically lyse 
target cells expressing foreign histocompatibility antigens, it was a  natural as- 
sumption that such cells would be the effector cells in skin allograft rejection. 
Since that time, a  great deal of circumstantial evidence has been presented to 
implicate cytotoxic T  lymphocytes (CTL) 1 in the phenomenon of graft rejection 
(reviewed  in  1).  It  should  be  stressed,  however,  that  all  of the  evidence  is 
circumstantial and that there probably is more than one mechanism to reject an 
aUogeneic skin graft (2, 3). The recent and much publicized work of Loveland, 
McKenzie, and their colleagues (4-6) directly challenges the notion that CTL 
are involved in murine skin graft rejection. These workers constructed T  ceil- 
deficient mice by thymectomizing adult CBA (H-2 k) mice, then irradiating and 
reconstituting them with T  cell-deficient syngeneic bone marrow. Such ATXBM 
mice were unable to reject C57BL/6 (H-2 b) skin grafts but an inoculum of primed 
CBA lymphoid cells restored their competence in this regard. The provocative 
finding  was  that  depleting  the  inoculum  of  Lyt-2  +  cells  with  a  monoclonal 
antibody plus complement (C')  had  no effect on  the adoptive transfer of the 
ability to reject. Lyt-l-specific antibody plus C' did deplete the effective cells but 
in this case (CBA mice that express the Lyt-l.1 allele), the anti-Lyt-1 sera killed 
all T  cells. 
Although their experimental result seemed clear, in that recipients of antigen- 
primed Lyt-2-depleted cells did reject skin grafts, it was formally possible that 
host-derived T  cells,  including CTL,  were also  contributing to  the response. 
However, a functional analysis of the adoptive hosts after rejection of the skin 
grafts was not performed. We realize that it is very difficult to make truly T  cell- 
free  mice:  nude  mice  (7-10)  as  well  as  ATXBM  mice  (11)  contain  T  cell 
precursors including CTL.  Therefore, we designed experiments which used a 
more stringent  protocol  for T  cell  depletion  of ATXBM  hosts and  we  used 
alloantigen-primed Thy-l.1  T  cells to transfer immunity to congeneic Thy-l.2 
ATXBM hosts.  This scheme enabled us to distinguish between activity due to 
the adoptively transferred cells (Thy-1.1) and the host-derived T  cells (Thy-1.2). 
Using minor histocompatibility antigens as a graft barrier, we demonstrated that 
Lyt-2-depleted as  well  as  Lyt-l-depleted  immune  spleen  cells  could  transfer 
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immunity to ATXBM  hosts that  themselves do not reject grafts.  However, our 
results showed that adoptive hosts which have received anti-Lyt-2 plus C'-treated 
immune spleen cells and have rejected skin grafts contain graft-specific CTL of 
host origin. Furthermore, when ATXBM mice are skin grafted while the host T 
cell  response  is absent,  donor-derived  CTL  are  detected  even  in  animals  that 
received anti-Lyt-2 plus C'-treated immune cells. We conclude that the question 
whether CTL are the effector cells in graft rejection is still open, but we maintain 
that the experiments of Loveland et al.  (4) do not provide any strong evidence 
against their involvement. 
Materials and  Methods 
Mice.  C57BL/6J (H-2  b, Thy-l.2; designated here as B6.Thy-l.2) were obtained from 
the vivarium at Scripps Clinic and Research Foundation. BALB.B (H-2  b) mice and C57BL/ 
Ka (H-2  b,  Thy-l.1  [B6.Thy-l.1]) were obtained  from I.  L.  Weissman,  Department of 
Pathology, Stanford University Medical Center Stanford, CA. 
Monodonal Antibodies.  Monoclonal antibodies used for cell depletions were: 13-4, anti- 
Thy-l.2 (12); 22.1, anti-Thy-l.1 (12); T24/31.7 (T24) from a rat-mouse hybridoma that 
recognizes a mouse-specific determinant on Thy- 1 (13);  AD4(15), anti-Lyt-2.2 (14);  and 
C3PO, anti-Lyt-1.2 (15).  All antibodies were in the form of high titer ascites fluid. In our 
hands, both AD4 (15) and C3PO iyse ~50% of peripheral T cells from B 10 mice (14,  15). 
These are partially overlapping populations since ~ 16% of peripheral T cells are sensitive 
to both  antibodies.  In  functional  tests  on  in  vivo primed,  mixed  lymphocyte culture 
(MLC), boosted anti-minor CTL effectors, we find that >95% of such CTL are sensitive 
to anti-Lyt-2.2 plus C' whereas anti-Lyt-l.2 plus C' inactivates <20%  of effector CTL. 
Additionally,  when  primed  spleen  cells are  treated  before culture,  anti-Lyt-2 plus  C' 
treatment prevents the development of >98%  of specific cytotoxicity while  treatment 
with anti-Thy-1 plus C' removes all CTL activity. C' treatment alone or treatment with 
anti-Lyt-1 plus C' did not affect the CTL response. 
ATXBMMice.  2 d before use as bone marrow donors, B6.Thy-l.2 mice were given a 
single intraperitoneal injection of 200 t*l of rabbit anti-mouse thymocyte serum (Micro- 
biological Associates,  Bethesda,  MD).  Bone marrow cells from tibias and  femurs were 
depleted of Thy-1 ÷ cells by treatment with a  mixture of the  13-4 and T24 monoclonal 
antibodies at 4°C for 30 min at a cell concentration of 1.0  ×  107/ml in Hank's balanced 
salt solution. Rabbit serum as a source of C' was then added to adjust the cell concentration 
to 5.0 ×  106 cells/ml and the cells were incubated for 45 rain at 37°C, washed twice, and 
used for reconstitution of syngeneic, thymectomized, irradiated mice. B6.Thy-l.2 mice, 
5-7 wk old, were thymectomized and,  1-6 wk later,  were lethally irradiated (950 rad) 
with a  13VCs source and injected intravenously with  1.0 ×  10 7 or  2 x  106 anti-Thy-1 plus 
C'-treated bone marrow cells.  At the time of sacrifice, all ATXBM mice were examined 
and found to be completely thymectomized. 
Priming to Minor Histocompatibility  Antigens and Adoptive Transfer.  B6.Thy-1.1 mice were 
primed  to  minor  histocompatibility antigens  of the  BALB  background  with  a  single 
intraperitoneal injection of 2.0  ×  107 viable spleen cells from BALB.B mice. At least 4 
wk  later,  spleen  cells  were  removed  and  treated  with  C'  alone  or  with  monoclonal 
antibodies specific for Thy-l, Lyt-l.2, or Lyt-2.2 plus C', as described for bone marrow 
depletion above. After antibody treatments, 5.0 ×  106 viable recovered cells were injected 
intravenously into the ATXBM B6.Thy-l.2 mice on the same day the skin grafting was 
done. 
Skin Grafting.  ATXBM B6.Thy-l.2 mice were given a  single full thickness BALB.B 
skin  graft (0.6-1.0  cm  Diam) on the flank and the  dressings were removed 7  d  after 
grafting. Rejection was scored as complete necrosis of the graft. 
ML  C.  For secondary in vitro restimulation, 2.5 x  107 spleen cells from grafted animals 
were co-cultured  with  2.5  ×  107  irradiated  (1,000  rad  from a  l~7Cs source)  BALB.B 
stimulator cells in  20  ml of RPMI  1640  medium containing  5%  fetal calf serum,  10% LEFRANCOIS AND BEVAN  59 
supernatant from concanavalin A (Con A)-stimulated mouse spleen cells (16), and 50 mM 
a-methyl-~mannoside to block the action of residual Con A. Cultures were incubated for 
5 d in an atmosphere of 5% COs in air. 
Assay for CTL Activity and Thy-1 Typing.  MLC cells were harvested after 5 d, washed, 
resuspended in Hank's balanced salt solution containing 2 mg/ml bovine serum albumin, 
and divided into three aliquots. Cells were treated either with C' alone, 22.1  (anti-Thy- 
1.1)  plus C', or a  mixture of 22.1  and  13.4  (anti-Thy-l.2) plus C' as described above. 
After treatment, the cells were washed and assayed in threefold serial dilutions for lysis 
of'~lCr-labeled target cells. 
The concentrations of anti-Thy-1 antibodies and C' used for typing CTL activity were 
shown  to  be  sufficient  for allele-specific killing in  control  experiments  using  in  vitro 
generated CTL from B6.Thy-l.2 and B6.Thy-1.1 mice. Con A blasts for target cells were 
prepared from spleen cells after removal of erythrocytes with Tris-ammonium chloride 
by culturing for 3 d  1.0  ×  107 cells in 20 ml of RPMI 1640 medium containing 5% fetal 
calf serum, 2.5/~g/ml Con A, and  10% supernatant derived from secondary MLC (17). 
Con  A  blasts  were  incubated  with  ~x-methyl-D-mannoside  before  use.  The  assay  was 
performed in 96-well round-bottomed microtiter plates (Costar, Cambridge, MA). After 
the addition of effector cells to plates containing  1.0  ×  104 target cells/well, the plates 
were centrifuged for 3 min at 800 rpm to initiate cell contact and incubated at 37°C for 
4 h.  Percent specific lysis was calculated as:  100  ×  [(cpm released with effectors -  cpm 
released alone)/(cpm released by detergent -  cpm released alone)]. 
Results 
Effect of T  Cell Subset Depletion  on Skin  Graft Rejection.  Since previous results 
had  indicated  that  the  treatment  of graft-immune spleen  cells  with  anti-Lyt-2 
antibody plus  C'  had  no  effect on  their  ability  to  transfer  skin  graft  rejection 
across a totally allogeneic barrier (4), we attempted to confirm these results using 
minor histocompatibility antigen-different skin grafts. B6.Thy-1.2 ATXBM mice 
were grafted with BALB.B skin and inoculated with BALB.B immune B6.Thy- 
1.1  spleen  cell populations.  By using  this pair of Thy-1  congeneics,  the  T  cell 
contribution of the ATXBM  host could be assessed relative to the activity of the 
adoptively transferred T  cells. The experiment shown in Table I used ATXBM 
hosts that had been irradiated and bone marrow reconstituted 6  wk before skin 
TABLE  I 
Both Lyt-1- and Lyt-2-depleted Adoptively Transferred Immune T Cells 
Can Induce Graft Rejection in ATXBM Mice Long After 
Reconstitution * 
Treatment of transferred  Number  of  Graft survival (days)*  cells  recipients 
C' only  4  12.0 _+ 0.8 
Anti-Lyt-l.2 pluc C'  5  18.5 :t: 2.5 
Anti-Lyt-2.2 plus C'  4  17.3 _+ 2.8 
No cells transferred  3  > 19, >26, >26  ! 
* 6 wk after reconstitution of thymectomized, irradiated B6.Thy-1.2 mice 
with T cell-depleted syngeneic bone marrow, the mice were grafted with 
BALB.B skin and injected intravenously on the same day with 5 X 10  6 
immune B6.Thy- 1.1 spleen cells that had been subjected to the indicated 
treatments. 
* Mean survival time ___ SD of BALB.B skin grafts. 
0 Skin graft intact on the indicated day of sacrifice. 60  SKIN  GRAFT  REJECTION 
grafting.  ATXBM  hosts  that  did  not  receive an  inoculum  of immune  cells 
retained their  grafts throughout the period of observation.  Recipients of C'- 
treated  immune  cells  rejected  their  grafts  in  12  d.  Prior  depletion  of the 
transferred immune spleen cells with anti-Lyt-1.2 or anti-Lyt-2.2 plus C' allowed 
a slight prolongation of graft survival but both populations were able to induce 
rejection in all recipients. 
Host  T  Cells Can  Contribute  to  the  Graft-specie  Response in  ATXBM  Mice. 
Although untreated ATXBM graft recipients are clearly unable to reject skin 
grafts  on  their  own,  it  was  possible  that  the  transfer  of immune spleen  cell 
populations could trigger the expansion of host T  cell precursors. Thus, at the 
time of rejection or shortly thereafter, the spleens of grafted mice were assayed 
for CTL activity. On days 19 and 21 after grafting, MLC were established from 
the spleens of graft recipients using irradiated BALB.B spleen cells as stimulators 
in the presence of 10% mouse spleen Con A supernatant. After 5 d, the cultures 
were assayed  for  cytotoxicity on  BALB.B  and  B6  target  cells and  the  CTL 
effector cells were typed using Thy-1.1- and Thy-l.2-specific antibodies plus C' 
(Fig. 1). In animals that received C'-treated cells or Lyt-1.2-depleted populations, 
the CTL response to graft-specific minor histocompatibility antigens was predom- 
inantly donor derived, i.e.,  the CTL activity was sensitive to anti-Thy-l.1  plus 
C'  treatment (Fig.  1A  and B).  In  these and  all  other  cases,  cytotoxicity was 
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FIGURE  l.  Spleen ceils from ATXBM  B6.Thy-l.2  mice bone  marrow reconstituted  6  wk 
before skin grafting and adoptive transfer of immune B6.Thy-1.1 spleen cells were stimulated 
in culture for 5 d with irradiated BALB.B spleen cells.  On the day of assay,  the effector cells 
were treated with C' alone (I), anti-Thy-l.1  plus C' (O), or anti-Thy-l.1  plus anti-Thy-l.2 
plus  C'  (A)  and  assayed  on  BALB.B or  B6  Con  A  blasts.  No  significant cytotoxicity was 
observed on B6 target cells. Treatments of BALB.B-immune B6.Thy-1.1 spleen cells adoptively 
transferred into graft recipients were as follows: (A) C' only, (B) anti-Lyt-1 plus C', (C and D) 
anti-Lyt-2 plus C'. LEFRANCOIS  AND BEVAN  61 
specific since B6 target cells were never lysed to a  significant degree (data not 
shown).  Although a  percentage of the  response  in  some of the animals  that 
received C'-treated or Lyt-1.2-depleted cells was clearly of host origin, the most 
striking example of host-derived CTL activity occurred in animals receiving Lyt- 
2.2-depleted immune spleen cells (Fig.  1 C and D).  In two of the animals that 
received Lyt-2-depleted cells, virtually the entire CTL response was due to host 
T  cells (Fig.  1 C and D). In a third animal, ~50% of the CTL response was host 
derived while a fourth exhibited no BALB.B-specific CTL. Since ATXBM hosts 
not receiving immune cells did not reject their skin grafts and showed no CTL 
activity, these results indicate that when the graft-immune donor cells are treated 
with anti-Lyt-2 plus C', the remaining cells are able to provide sufficient help to 
trigger host  CTL precursors to,  at  the least,  become primed to  graft-specific 
antigens. It should be noted that all of these animals rejected their skin grafts 
whereas animals that did not receive sensitized cells showed no CTL activity and 
did not reject their grafts (Table I). 
Graft  Rejection  in  ATXBM Mice Early After Bone Marrow Reconstitution.  Since 
host-derived T  cell responses could be detected in skin-grafted ATXBM  mice 
that had been irradiated and bone marrow reconstituted 6  wk previously, we 
attempted to circumvent this endogenous response by grafting mice only  1-2 
wk after they received a smaller number (2 x  106) of Thy-1- bone marrow cells. 
Mice receiving C'-treated or anti-Lyt-l.2  plus  C'-treated immune B6.Thy-l.1 
cells on the day of skin grafting normally rejected grafts (range, 13-17 d) (Table 
II). Similarly, in  the recipients of anti-Lyt-2.2 plus C'-treated cells, grafts were 
rejected, although the rejection time was prolonged in some cases (range, 13-21 
d). Rejection was not observed if anti-Thy-1 plus C'-treated immune cells were 
injected, or if animals received no  immune cells.  Thus,  when ATXBM  hosts 
were used only  1 wk after bone marrow reconstitution at a  time when host- 
derived T  cell  activity should  be  low,  graft  rejection  proceeded normally in 
animals given either Lyt-1- or Lyt-2-depleted immune cells. 
Graft-spec~c  Cytotoxicity  Is  Donor  Cell-derived  in  ATXBM  Mice  Used  Early  After 
Reconstitution.  Functional  testing of spleen  cells  from animals  that  had  been 
TABLE  II 
Skin Grc~ Rejection in ATXBM Mice Soon After Bone Marrow 
Reconstitution * 
Treatment of transferred  Number of  Graft survival (days)*  cells  recipients 
C' only  4  15.0 _+ 0.8 
Anti-Lyt-l.2 plus C'  5  14.4 _+ 0.6 
Anti-Lyt-2.2 plus C'  9  17.1  _+ 2.7 
Anti-Thy-1 plus C'  5  >19, >19, >25, >44, >44  ~ 
No cells transferred  5  >t9, >21, >21, >25, >35  § 
* 1 wk after reconstitution of thymectomized, irradiated B6.Thy-l.2 mice with 
6  2  ×  10  T  cell-depleted syngeneic bone marrow, the mice were grafted with 
6  BALB.B skin and injected intravenously on the same day with 4 ×  10  immune 
B6.Thy-1.1 spleen cells that had been subjected to the indicated treatments. 
* Mean survival time +  SD of BALB.B skin grafts. 
§ Graft intact on indicated day of sacrifice. 62  SKIN  GRAFT  REJECTION 
grafted  1 wk after bone marrow reconstitution revealed that any CTL activity 
against BALB minor histocompatibility antigens was wholly donor T  cell derived 
(Fig.  2, Table  III).  MLC were set up with irradiated  BALB.B stimulators and 
medium containing  10%  mouse Con  A  supernatant  between days  19  and  26 
after skin grafting.  Animals that had received C'-treated  (Fig.  2A) or Lyt-l.2- 
depleted cells (Fig. 2B) showed a  high specific cytotoxicity for BALB.B targets 
that was completely sensitive to anti-Thy-1.1 plus C'. Unexpectedly, some animals 
that  had  received an  inoculum treated  with anti-Lyt-2  plus C'  also  exhibited 
donor-derived CTL activity.  In the recipients of anti-Lyt-2-treated  cells,  MLC 
cells  derived  from  four  of  six  animals  tested  gave  significant  graft-specific 
cytotoxicity while cells from two animals showed no CTL activity against BALB.B 
targets (Table III). All of these animals rejected their grafts and no correlation 
was seen  between  the level of cytotoxicity in  MLC and  the rejection time of 
BALB.B grafts. This point is further exemplified by the fact that some animals 
receiving immune cells treated with anti-Thy-1 plus C' were also able to generate 
cytotoxic activity against BALB.B targets while retaining their skin grafts (Fig. 
2 C, D, Table II). 
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FZGURE 2.  Spleen cells from ATXBM B6.Thy-l.2  mice bone marrow  reconstituted  1 wk 
before skin grafting and adoptive transfer of immune B6.Thy-1.1 spleen cells were stimulated 
in culture for 5 d with irradiated BALB.B spleen cells.  On the day of assay,  the effector cells 
were treated with C' alone (O), anti-Thy-l.l  plus C' (O), or anti-Thy-l.1  plus anti-Thy-l.2 
plus  C'  (/x) and  assayed  on  BALB.B or  B6  Con  A  blasts.  No significant cytotoxicity was 
observed on B6 target cells. Treatments of BALB.B-immune B6.Thy-1.1 spleen cells adoptively 
transferred into graft recipients were as follows: (A) C' only, (B) anti-Lyt-I plus C', (C) anti- 
Lyt-2 plus C', (D) anti-Thy-1 plus C'. LrFRANCOIS AND BEVAN  63 
TABLE  III 
Relative Contribution of Adoptively Transferred Immune (Thy-1. I) and Host 
T Cells (Thy-1.2) to Graft-specific Cytotoxicity* 
Percentage 
of 
Treatment of  Animal  cytotoxicity  Lytic units/  Graft 
transferred cells  due to  106 cells  rejection 
donor T 
cells* 
Experiment l 
C'  1  100  0.9  + 
2  66  9.1  + 
3  100  18.6  + 
Anti-Lyt-1.2+C'  1  100  14.4  + 
2  66  0.8  + 
3  90  4.5  + 
4  100  2.7  + 
Anti-Lyt-2.2+C'  1  <1  23.4  + 
2  50  0.9  + 
3  5  0.8  + 
4  --  <0.1  + 
No cells transferred  1,2,3  <0.1  NR ! 
Experiment 2 
C'  1  100  29.5  + 
2  100  14.1  + 
3  100  9.8  + 
Anti-Lyt-l.2+C'  I  100  47.9  + 
2  100  18.2  + 
3  I00  2.1  + 
4  100  1.6  + 
Anti-Lyt-2.2+C'  1  100  12.9  + 
2  100  11.5  + 
3  100  1.7  + 
4  100  1.5  + 
5  --  <0.1  + 
6  --  <0.1  + 
No cells transferred  1,2,3  --  <0.1  NR 
* ATXBM B6.Thy-1.2 mice were used as recipients of BALB.B skin gratis and 
immune  B6.Thy-l.1  spleen cells  6  wk  after  irradiation  and  bone  marrow 
reconstitution (experiment 1; see Table I) or  1 wk after irradiation and bone 
marrow reconstitution (experiment 2; see Table If). 
* The percentage cytotoxicity due to donor or host CTL was calculated from 
comparisons of complete titrations of effector cells treated with C' alone, anti- 
Thy-l.1 plus C', or anti-Thy-l.1 plus anti-Thy-l.2 plus C'. BALB.B and B6 3 
d  Con A  blasts were used as targets; range of spontaneous release was 17-31%. 
No cytotoxicity against B6 targets was observed in any of the assays. One lyric 
unit is defined as the number of effector cells required to achieve 30% specific 
lysis of target cells. 
0 No graft rejection. The BALB.B skin graft was in good condition at the time 
the animal was sacrificed for MLC. 64  SKIN  GRAFT  REJECTION 
Discussion 
The  studies  reported  here  were  undertaken  partly  to  assess the  validity of 
using ATXBM  hosts as  "T cell  free"  models in  studies of skin graft rejection. 
This was prompted by a number of recent studies (4, 6) that used ATXBM mice 
and suggested that  Lyt-2  + cells had no role in  skin  graft rejection, and by the 
knowledge that ATXBM mice are not truly T  cell deficient (11). A summary of 
our  results  is  shown  in  Table  III.  In  direct  contrast  to  the  recent  work  of 
Loveland et al.  (1,  4-6),  Lyt-1  depletion of transferred  graft-immune  cells did 
not  remove  the  ability  of these  cells  to  reject  grafts  (experiments  1  and  2). 
However, a major difference between our work and that of Loveland et al. is in 
the reactivity of the  Lyt-l-specific antibody used.  In  their studies,  Loveland et 
al.  used  CBA  mice  as  recipients  in  which  100%  of T  cells were  removed  by 
treatment  with anti-Lyt-l.1  plus C'  (in  fact,  their  antibody depleted a  greater 
number of cells than did treatment with anti-Thy-1  plus C'), while the anti-Lyt- 
1.2 antibody we used reacted with -50% of B6 T  cells. Indeed, anti-Thy-1  plus 
C' treatment of transferred cells did prevent graft rejection. Thus,  Loveland et 
al.  were unable to functionally fractionate  T  cells by depletion of Lyt-1 + cells, 
since  this  would remove all  T  cells,  including  CTL.  In  our  experiment  1,  in 
which ATXBM mice reconstituted 6 wk previously were used as graft recipients, 
depletion of Lyt-2  + cells from the inoculum also did not affect graft  rejection. 
This result is identical to that of Loveland et al (4), where a similar protocol was 
used.  However,  we  examined  the  spleens  of  these  mice  shortly  after  graft 
rejection for graft-specific cytotoxicity and  found that  host-derived CTL were 
contributing significantly to the response. In mice receiving C'- or Lyt-1 plus C'- 
treated cells, the CTL response was predominantly donor T  cell derived and no 
graft-specific cytotoxicity developed in animals that did not receive immune cells. 
The important implication of these findings is that Lyt-1 + cells and/or accessory 
cells in the immune Lyt-2-depleted, adoptively transferred cells are able to trigger 
naive resident CTL precursors to react to graft-specific antigens. In a study using 
ATXBM  rats  that  had  been  given  an  inoculum  depleted of MRC-OX8  + cells 
(antibody  MRC-OX8  recognizes  CTL  and  most  natural  killer  cells),  a  large 
number  of MRC-OX8  + cells were  later  found in  rejecting  allografts  (18).  Al- 
though their origin was not determined, these cells were found only in rejecting 
allografts and  not in syngeneic grafts.  Thus,  although  the role of host-derived 
CTL in the rejection process is as yet unknown, we conclude that the involvement 
of Lyt-2  + cells in skin graft rejection cannot be ruled out. 
In  an  attempt  to  circumvent  the  host-derived  T  cell  response,  we  used  as 
recipients ATXBM mice that had been irradiated and bone marrow reconstituted 
only 1 wk previously (Table II and experiment  2, Table III). As in experiment 
1, Table III, all animals that received immune cells treated with C' alone, anti- 
Lyt-1,  or anti-Lyt-2  plus  C',  rejected  their  skin  grafts.  Animals  receiving  an 
inoculum  of cells  treated  with  anti-Thy-1  plus  C'  or  receiving  no  inoculum 
retained their grafts until  the time of sacrifice. When the spleens of these mice 
were assayed for graft-specific cytotoxicity, we found the host-derived response 
to  be undetectable.  However, spleens  from  animals  from  each  of the  groups 
(except  those  not  receiving  immune  cells)  contained  CTL  specific for  BALB 
minor histocompatibility antigens. Two important points are evident from these LEFRANCOIS  AND BEVAN  65 
results:  there appears  to  be  no  strict  correlation  between in  vitro  generated 
cytotoxicity and graft rejection and it is difficult to totally deplete spleen cells of 
a  particular subpopulation  of T  cells by conventional treatment with antibody 
and C'.  It is possible that a  small percentage of cells that are resistant to anti- 
Lyt-2 plus C' or anti-Thy-1 plus C' proliferate in vivo in response to the continual 
antigenic stimulation provided by the BALB.B skin graft. 
Since we were unable to totally deplete adoptively transferred cells of T  cell 
subsets and since an endogenous graft-specific response in  ATXBM mice was 
evident in some cases, we are unable to answer the question as to which functional 
T  cell type(s) is  ultimately responsible for skin graft rejection. Recent results 
have shown that  Lyt-l+2  + cells were essential  for rejection of pancreatic islet 
allografts (19) and in  local immunity against a  tumor cell allograft (20).  Addi- 
tionally, when rat  renal allografts were examined, the predominant cell  type 
found was of the T  suppressor/killer cell phenotype (21).  Although it may be 
difficult to  envision  the destruction of a  skin  graft solely by the one on  one 
cytolytic activity of CTL, it should be pointed out that CTL secrete lymphokines 
upon recognition of antigen that can activate accessory cells: All CTL  clones 
examined so far secrete immune interferon on contact with antigen (22-24).  In 
addition to its anti-viral action, immune interferon has macrophage-activation 
factor (MAF) activity (24, 25). This has been most clearly demonstrated by the 
use of recombinant mouse gamma interferon (25,  26). Thus, at the site of the 
graft bed, CTL will release MAF and recruit the activity of macrophages. It has 
also been recently reported that some CTL release interleukin 2  (27), though 
whether this lymphokine has a  role at the graft site is not known. Therefore, 
through soluble mediators plus their own lytic activity, CTL could be efficient 
initiators of graft rejection. We are currently designing experiments in which a 
more complete removal of T  cell subsets will allow us to determine if this is the 
case. 
Summary 
We have investigated which T cell subclass defined by cytolysis with monoclonal 
anti-Lyt-l.2  and anti-Lyt-2.2 antibodies is required to adoptively transfer the 
ability to reject skin grafts.  B6.Thy-l.1  spleen cells immune to graft antigens 
were fractionated with antibody plus C' and transferred to adult thymectomized, 
irradiated, bone marrow-reconstituted (ATXBM)  B6.Thy-l.2  hosts that were 
simultaneously grafted with  BALB.B skin.  We found that when the ATXBM 
hosts were used 6  wk after irradiation and marrow reconstitution, both Lyt-1- 
depleted and  Lyt-2-depleted immune spleen cells could transfer the ability to 
promptly reject skin grafts. However, such ATXBM recipients of Lyt-2-depleted 
cells that had rejected skin grafts were found to contain graft-specific CTL that 
were largely of host (B6.Thy-1.2) origin. When ATXBM hosts were used for the 
experiment 1 wk after irradiation and marrow reconstitution, no host-derived 
graft-specific CTL  could  be  detected.  However,  graft  rejection  occurred  in 
recipients of anti-Lyt-1- or anti-Lyt-2 plus C'-treated immune cells and specific 
CTL were generated from spleen cells of both groups. Thus, in the absence of 
a  host-derived  response,  adoptively  transferred  immune  Lyt-2  +  cells,  either 
resistant to, or that escaped from, antibody plus C' treatment, are able to expand 66  SKIN GRAFT  REJECTION 
in  response  to the antigenic stimulus provided by the graft.  A  more complete 
elimination of specific T  cell subclasses is therefore needed to assess the relative 
contribution of a particular subset to the graft rejection process. 
Received for publication 29 August 1983. 
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